Drug Trial Radar · NCT06843239
Tibulizumab Systemic Sclerosis Understanding and Response Evaluation (TibuSURE)
Last checked: Nov 20, 2026Latest source record: Jul 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
80
Planned (sponsor's estimate)
Start
Feb 6, 2025
Primary completion
May 2027
Study completion Jan 2028
Sponsor
- Lead sponsor
- Zura Bio IncIndustry
- Sponsor type
- Industry
- First posted
- Feb 24, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study is a Phase 2, multi-center, randomized, double-blind, placebo-controlled study to evaluate the effects of tibulizumab over 24 weeks (Period 1) in adult participants with systemic sclerosis, followed by an open-label extension period where all active participants will receive tibulizumab and will be evaluated for an additional 28 weeks (Period 2)
Conditions
- Systemic Sclerosis (SSc)
- Scleroderma
Interventions
TibulizumabBiological
Anti BAFF/IL-17 antibody
PlaceboOther
Placebo (inactive)
Primary outcomes
What the sponsor says the trial is designed to measure.
- [Period 1] Change from baseline in modified Rodnan Skin Score (mRSS) at 24 weeksTime frame: Week 24
- [Period 2] Safety and tolerability of tibulizumabTime frame: Week 52
Locations
60 sites in 10 countries. Site status is shown where the registry gives one.
UCSD Altman Clinical and Translational Research Institute Center for Clinical Research
La Jolla, California
UCLA Department of Medicine
Los Angeles, California
IRIS Research and Development LLC
Plantation, Florida
University of Iowa
Iowa City, Iowa
Massachusetts General Hospital
Boston, Massachusetts
University of Michigan Hospital
Ann Arbor, Michigan
Rheumatology Associates
Arlington, Texas
Organización Médica de Investigación
Buenos Aires, Argentina
Centro de Investigación y Prevención Cardiovascular-Arenales
Buenos Aires, Argentina
Hospital General de Agudos Dr. José María Ramos Mejia
Buenos Aires, Argentina
Instituto de Investigación Clínica TyT
Buenos Aires, Argentina
Centro Medico de Estudios Clinicos y Farmacovigilancia (CECYF)
Buenos Aires, Argentina
Consultorios Médicos Dr. Doreski
Buenos Aires, Argentina
Consultora Integral de Salud Centro Médico Privado
Córdoba, Argentina
Instituto CER S.A.
Quilmes, Argentina
AES - AS - Clinica Mayo de Urgencias
San Miguel de Tucumán, Argentina
STAT Research S.A.
Buenos Aires, Buenos Aires, Argentina
Centro de Investigaciones Médicas Tucumán
San Miguel de Tucumán, Tucumán Province, Argentina
CTR Estudios Clinicos
Santiago, Chile
Enroll SpA
Santiago, Chile
Centro de especialidades médicas Vanguardia
Temuco, Chile
Clinical Research Chile SpA
Valdivia, Chile
Centro de Estudios Clinicos Victoria Limitada (Cevic)
Victoria, Chile
Dermacross Clinica Dermatologica
Vitacura, Chile
Debreceni Egyetem Klinikai Kozpont Nagyerdei Campus
Debrecen, Hungary
Pécsi Tudomanyegyetem - Vasvari Pal u.
Pécs, Hungary
Mediadvance Clinical
Chihuahua City, Mexico
PanAmerican Clinical Research
Guadalajara, Mexico
Medical Care and Research S.A. de C.V.
Mérida, Mexico
Centro de Investigación y Tratamiento Reumatológico S.C
Miguel Hidalgo, Mexico
Oaxaca Site Management Organization - Clinic - OSMO - PPDS
Oaxaca City, Mexico
M2M Med-ul.
Chorzów, Poland
Malopolskie Badania Kliniczne Sp. z o.o.
Krakow, Poland
Malopolskie Centrum Kliniczne
Krakow, Poland
Centrum Medyczne Plejady
Krakow, Poland
Santa Familia PTG Łódź
Lodz, Poland
Twoja Przychodnia NCM
Nowa Sól, Poland
Twoja Przychodnia PCM - ul.
Poznan, Poland
Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji
Warsaw, Poland
Klinika Reuma Park sp . zoo Sp.k.
Warsaw, Poland
Showing 40 of 60 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.